Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics
about
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsRemoving T-cell epitopes with computational protein design.Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis.Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virusIn Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.Immune camouflage: relevance to vaccines and human immunology.Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50MTNFRSF1Avariant
P2860
Q28066498-B6D23433-4A3E-40F0-97B9-8DD435AC1524Q30362724-045FAD32-9DFF-4227-A1A6-9D2127182CC7Q34555552-C354437D-D6CE-4FCB-B383-465FC0319374Q35076835-6553D716-56F1-4221-A19F-8CD51E373166Q36076112-6C6554A6-6E79-4C34-BDA6-CA95E023CC75Q36255850-673980FC-9F33-49A7-802D-B3156E5E6B32Q37517101-C48A0668-9C0E-4128-B45E-DF750AF0FD77Q38974661-64CA69A0-75B6-44C7-9039-B63710F783EBQ39080439-614CC143-6222-46B3-BC94-43A834BF43DFQ47436657-B3622EB6-85AB-451A-9DFD-489670D65D91Q47716213-8FFCB84A-6F2B-44F2-8194-345267F619F4Q56974514-8515BD31-7A75-4F4E-9A43-5AC9A41D0FB9
P2860
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Beyond humanization and de-imm ...... he immunogenicity of biologics
@ast
Beyond humanization and de-imm ...... he immunogenicity of biologics
@en
Beyond humanization and de-imm ...... he immunogenicity of biologics
@nl
type
label
Beyond humanization and de-imm ...... he immunogenicity of biologics
@ast
Beyond humanization and de-imm ...... he immunogenicity of biologics
@en
Beyond humanization and de-imm ...... he immunogenicity of biologics
@nl
prefLabel
Beyond humanization and de-imm ...... he immunogenicity of biologics
@ast
Beyond humanization and de-imm ...... he immunogenicity of biologics
@en
Beyond humanization and de-imm ...... he immunogenicity of biologics
@nl
P2093
P2860
P3181
P1476
Beyond humanization and de-imm ...... he immunogenicity of biologics
@en
P2093
Frances Terry
Leslie Cousens
William Martin
P2860
P304
P3181
P356
10.1586/17512433.2013.835698
P407
P577
2013-11-01T00:00:00Z